EQS-News

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease 21.05.2025, 14:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Galimedix, Inc. / Key word(s): Scientific publication
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

21.05.2025 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

  • Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.
  • Improves Memory and Behavior: Preclinical testing shows significant improvements in spatial learning and memory in transgenic models of Alzheimer’s disease.
  • Targets Core Pathologies: GAL-201 reduces Aβ-induced neuroinflammation and even lowers the number of toxic Aβ plaques, addressing key drivers of disease progression.

Kensington, MD, USA and Munich/Martinsried, Germany, May 21, 2025 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the publication of compelling new data on the mechanism of GAL-201 in counteracting the damaging effects of amyloid-beta (Aβ) oligomers – soluble protein aggregates known to disrupt memory circuits and contribute to disease pathology in Alzheimer’s disease (AD). The article, entitled, GAL-201 as a Promising Amyloid-β-Targeting Small-Molecule Approach for Alzheimer’s Disease Treatment: Consistent Effects on Synaptic Plasticity, Behavior and Neuroinflammation, was published in the peer-reviewed International Journal of Molecular Sciences and shows the compound’s disease modifying effect in preclinical models of AD. The article can be found here.

The published experiments demonstrate that the Aβ-aggregation modulator GAL-201, which targets the misfolded (aggregation-prone) Aβ-monomers, is not specific to Aβ1-42 only, but also targets other subtypes of Aβ. By interfering in the Aβ-aggregation cascade at source, toxic oligomers and protofibrils are not formed, resulting in a better cognitive outcome. Even after a single injection of GAL-201, AD animal models exhibited marked improvements in learning and memory behaviors. Further in vitro experiments showed that this protective effect of GAL-201 is accompanied by beneficial effects on synapse dynamics as well as anti-inflammatory effects. In addition, the compound also led to a measurable reduction in the number of Aβ plaques, further supporting its potential as a disease-modifying drug.

Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix, said: “These new results strengthen the positioning of GAL-201 as both a symptom-relieving and a disease-modifying therapeutic agent for Alzheimer’s disease. The compound targets core features of the disease, including synaptic dysfunction, neuroinflammation, and Aβ plaque formation, thereby fighting progressive neurodegeneration and cognitive decline. We believe that GAL-201 and Galimedix’s sister program GAL-101 are promising candidates for a patient-friendly oral treatment for this devastating disease.”

GAL-201 is currently in preclinical testing. GAL-101, a compound closely related to GAL-201, is currently under investigation in a Phase 1 study. In addition, GAL-101 eye drops are being investigated in the Phase 2 eDREAM study in patients with dry age-related macular degeneration, an Aβ-associated retinal disease. 

 

About Galimedix Therapeutics, Inc. 

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease - Galimedix’s initial areas of focus.

Contact 
Alexander Gebauer, MD, PhD 
Galimedix Therapeutics, Inc. 
Co-founder and Executive Chairman  
info@galimedix.com  

Media inquiries: 

Anne Hennecke / Lydia Robinson Garcia   U.S.  
MC Services AG    Laurie Doyle  
Tel: +49 (0)170 7134018  Tel: +1-339-832-0752 
galimedix@mc-services.eu    


21.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2142602  21.05.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

Created with Highcharts 11.4.8Values19 Jun02:0004:0006:0008:0010:0012:0014:0016:0018:0020:0022:0023.00023.05023.10023.15023.20023.25023.30023.350
23.053 (21:17) -1,13 % -263,00
k.A. (k.A.) k.A. k.A.
k.A. (k.A.) k.A. k.A.
BörsenNEWS.de
Registrieren
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer